The International Coordinating Group, the body that rations scarce emergency vaccines from the global stockpile, released an initial 70,000 doses of Ervebo to DR Congo on 20 August at the government's request1. Twenty thousand are allocated to a Phase 3 trial against Bundibugyo; 50,000 go to frontline and health workers. "It is not known whether Ervebo may be protective against the Bundibugyo virus in humans," WHO said, citing laboratory and animal data that suggest some protection2.
Ervebo is licensed against Zaire ebolavirus. Its protection comes from antibodies raised against that species' surface glycoprotein, and whether those antibodies bind well enough to a Bundibugyo glycoprotein is a question about molecular shape that no amount of urgency answers. The allocation splits the difference: a trial arm designed to produce an answer, and a much larger tranche given to the people at highest risk on the strength of a hypothesis.
A trial arm during an active outbreak has a narrow window. Effectiveness is measured by comparing infections among the vaccinated with infections among those not yet vaccinated, so the study needs enough incidence to accumulate cases faster than the response suppresses them. Too much transmission and the ethics of a comparison group tighten; too little, and the arm never reaches a readable signal. Watch that constraint rather than the dose count.
Oxford's ChAdOx1 BDBV began Phase 1 dosing only in late July and Hilleman's Bundibugyo-specific candidate entered trial production only on 31 July, so a Zaire vaccine and a research protocol are the whole of this month's deployable stock.
Diagnostics moved in the same week, in two pieces. The European Commission is procuring €2.5 million of rapid molecular point-of-care tests and instruments for donation to Africa CDC, with first deliveries starting in August3. On 24 August it added €2.1 million of open-platform polymerase chain reaction (PCR) tests for WHO's Hub for Global Health Emergencies Logistics in Dubai, taking total EU diagnostic support for the outbreak to €4.6 million4. The two buy different things. A point-of-care test moves the diagnosis to the patient, clearing a negative the same day and freeing an isolation bed. Open-platform PCR runs on whatever machines a laboratory already owns rather than one manufacturer's cartridges, which matters when the alternative is a sole-source contract. Neither release says how many tests the money buys.
